Veru Inc. Q3 2025 Earnings Recap

Veru Inc. reported promising results from its Phase 2b clinical trial for Inovasaram, demonstrating effective preservation of lean mass while enhancing fat loss in older patients using semaglutide for weight management.

Key Takeaways

• Inovasaram treatment in conjunction with semaglutide achieved 100% preservation of lean mass, significantly outperforming the placebo group (p < 0.001).
• Participants receiving Inovasaram exhibited a dose-dependent fat loss, with the six mg group achieving a 42% greater reduction compared to the placebo (p = 0.017).
• The safety profile of the Inovasaram and semaglutide combination was confirmed, with positive results seen during the maintenance extension phase, indicating reduced weight regain post-treatment.
• After discontinuation of semaglutide, the three mg Inovasaram significantly limited weight regain by 46% compared to the placebo, highlighting its potential for long-term weight management.